Skip to main content
. 2020 Jul 14;38(33):5268–5277. doi: 10.1016/j.vaccine.2020.05.084

Table 2.

Cold chain capacity, interviews with 96 health facility managers in 10 countries.

Does your facility have onsite cold chain capacity for vaccine storage?
PAB < 90% PAB ≥ 90% Group 1 Group 2 Group 3 Group 4 Total
No n (%) 3 (6.38) 1 (2.4) 4 (8.9) 0 (0) 0 (0) 4 (4.2)
Yes n (%) 44 (93.62) 41 (97.6) 41 (91.1) 33 (1 0 0) 17 (1 0 0) 91 (95.8)
Total 47 (1 0 0) 42 (1 0 0) 44 (1 0 0) 33 (1 0 0) 17 (1 0 0) 95 (1 0 0)
Fisher's exact 0.62 0.046/0.009* 0.293 1
Does your facility have a sufficient supply of TTCV?
PAB < 90% PAB ≥ 90% Group 1 Group 2 Group 4 Group 3 Total
No n (%) 2 (4.35) 6 (14) 6 (13.6) 2 (6.06) 0 (0) 8 (9)
Yes n (%) 44 (95.65) 37 (86) 38 (86.4) 31 (93.94) 18 (1 0 0) 87 (91)
Total 46 (1 0 0) 43 (1 0 0) 44 (1 0 0) 33 (1 0 0) 18 (1 0 0) 95 (1 0 0)
Fisher's exact 0.149 0.139 0.710 0.345
Have you experienced any stock outs of TTCV at your facility?
PAB < 90% PAB ≥ 90% Group 1 Group 2 Group 4 Group 3 Total
No n (%) 41 (89.1) 31 (72.1) 32 (72.7) 29 (87.88) 17 (94.44) 78 (82.1)
Yes n (%) 5 (10.9) 12 (27.9) 12 (27.3) 4 (12.12) 1 (5.56) 17 (17.9)
Total 46 (1 0 0) 43 (1 0 0) 44 (1 0 0) 33 (1 0 0) 18 (1 0 0) 95 (1 0 0)
Fisher's exact 0.059/0.131* 0.033/0.133* 0.401 0.180/0.092*

Group 1: very limited potential (VLimP)

Group 2: Limited potential (LimP)

Group 3: Moderate potential (ModP)

Group 4: High potential (HighP)

*

p-value from generalized estimating equations